Amylin Receptor Agonist

Mechanism

Related News

Lilly Amasses $1.5B Stockpile for Oral Obesity Drug as Logistics and Amylin Sectors Surge

Jul 25, 2026

Eli Lilly builds $1.5B stockpile for oral obesity drug orforglipron; study shows GLP-1s cut cancer risk; logistics firms invest in cold chain; and amylin drug race heats up with $19B in deals.

Viking Therapeutics Advances VK2735 Obesity Program Into Phase 3 Amid Widening Losses

Feb 13, 2026

Viking Therapeutics reported a full-year 2025 net loss of $359.64 million as it rapidly advanced its obesity candidate VK2735 into Phase 3 trials, with both injectable and oral formulations showing double-digit weight loss in earlier studies.